Analyst Ratings For Conatus Pharmaceuticals (NASDAQ:CNAT)
Today, Roth Capital initiated coverage on Conatus Pharmaceuticals (NASDAQ:CNAT) with a Buy with a price target of $20.00.
Some recent analyst ratings include
- 2/8/2018-Roth Capital initiated coverage with a Buy rating.
- 11/2/2017-HC Wainwright Reiterated Rating of Buy .
- 10/6/2017-Seaport Global Securities Reiterated Rating of Buy.
- 8/3/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 5/15/2017-Aegis Reiterated Rating of Buy.
- 3/15/2017-FBR & Co Reiterated Rating of Outperform.
Recent Insider Trading Activity For Conatus Pharmaceuticals (NASDAQ:CNAT)
Conatus Pharmaceuticals (NASDAQ:CNAT) has insider ownership of 13.90% and institutional ownership of 35.84%.
- On 4/8/2015 Daniel L Kisner, Director, bought 4,000 with an average share price of $5.75 per share and the total transaction amounting to $23,000.00.
- On 7/30/2013 David F Hale, Director, bought 2,588 with an average share price of $11.00 per share and the total transaction amounting to $28,468.00.
- On 7/30/2013 Luke Evnin, Major Shareholder, bought 165,265 with an average share price of $11.00 per share and the total transaction amounting to $1,817,915.00.
- On 7/30/2013 Steven J Mento, CEO, bought 13,800 with an average share price of $11.00 per share and the total transaction amounting to $151,800.00.
Recent Trading Activity for Conatus Pharmaceuticals (NASDAQ:CNAT)
Shares of Conatus Pharmaceuticals closed the previous trading session at 5.11 up +0.07 1.39% with 5.539999961853027 shares trading hands.
